Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by WOMER, K. L.
Right arrow Articles by SAYEGH, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WOMER, K. L.
Right arrow Articles by SAYEGH, M. H.
J Am Soc Nephrol 12:2500-2506, 2001
© 2001 American Society of Nephrology


BRIEF COMMUNICATIONS

Indirect Allorecognition of Donor Class I and II Major Histocompatibility Complex Peptides Promotes the Development of Transplant Vasculopathy

KARL L. WOMER*, JAMES R. STONE{dagger}, BARBARA MURPHY{ddagger}, ANIL CHANDRAKER* and MOHAMED H. SAYEGH*

* Laboratory of Immunogenetics and Transplantation, Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Masachussets
{dagger} Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Masachussets
{ddagger} Renal Division, Mt. Sinai Medical School, New York, New York.

Correspondence to Dr. Mohamed H. Sayegh, Research Director, Laboratory of Immunogenetics and Transplantation, Renal Division, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115. Phone: 617-732-5259; Fax: 617-732-5254; E-mail: msayegh{at}rics.bwh.harvard.edu

Abstract

Abstract. Recent clinical and experimental evidence suggests that indirect allorecognition may promote the development of chronic rejection, but definitive experimental studies are lacking. To study the contribution of indirect allorecognition to chronic rejection, naïve Lewis (RT11) rats were immunized with synthetic Wistar Furth (WF) class II-RT1u.D (HLA-DR—like) or -RT1u.B (HLA-DQ—like) or class I-RT1u.A (HLA-A—like) peptides emulsified in complete Freund's adjuvant 7 d before transplantation (n = 5 to 7/group). Experimental and control animals then acted as recipients of fully mismatched WF vascularized cardiac allografts. Recipients received immunosuppression in the form of cyclosporine at a tapering dose that allows for long-term allograft survival. Animals were sacrificed at either 3 or 6 mo, with allograft arterial luminal occlusion scored on elastin stains by a blinded observer. At 3 mo, mean vessel scores were significantly higher in the RT1u.A-immunized versus class II—immunized and control groups (P < 0.05). By 6 mo, there was progression of chronic allograft vasculopathy and a significantly higher mean vessel score in the RT1u.A- and RT1u.D-immunized versus RT1u.B and control groups (P < 0.05). In vitro studies show evidence of shifting MHC allopeptide immunogenicity. It was concluded that T cells primed by specific donor class I and II MHC allopeptides promote the development of chronic vascularized allograft rejection. These novel observations provide definitive evidence of a link between indirect allorecognition and the development and progression of chronic rejection.




This article has been cited by other articles:


Home page
J. Immunol.Home page
G. Chalasani, Q. Li, B. T. Konieczny, L. Smith-Diggs, B. Wrobel, Z. Dai, D. L. Perkins, F. K. Baddoura, and F. G. Lakkis
The Allograft Defines the Type of Rejection (Acute versus Chronic) in the Face of an Established Effector Immune Response
J. Immunol., June 15, 2004; 172(12): 7813 - 7820.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
K. L. Womer and M. H. Sayegh
Donor Antigen and Transplant Tolerance Strategies: It Takes Two to Tango!
J. Am. Soc. Nephrol., April 1, 2004; 15(4): 1101 - 1103.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
A. D. Salama, N. Najafian, M. R. Clarkson, W. E. Harmon, and M. H. Sayegh
Regulatory CD25+ T Cells in Human Kidney Transplant Recipients
J. Am. Soc. Nephrol., June 1, 2003; 14(6): 1643 - 1651.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
H. Regele, G. A. Bohmig, A. Habicht, D. Gollowitzer, M. Schillinger, S. Rockenschaub, B. Watschinger, D. Kerjaschki, and M. Exner
Capillary Deposition of Complement Split Product C4d in Renal Allografts is Associated with Basement Membrane Injury in Peritubular and Glomerular Capillaries: A Contribution of Humoral Immunity to Chronic Allograft Rejection
J. Am. Soc. Nephrol., September 1, 2002; 13(9): 2371 - 2380.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
A. Herskowitz and A. A. Ansari
Are we clear about the mechanisms by which biopsy evidence of interstitial fibrosis following cardiac transplantation helps predict late post-transplant coronary artery disease?
J. Am. Coll. Cardiol., March 20, 2002; 39(6): 978 - 980.
[Full Text] [PDF]




HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP